X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA SANOFI INDIA PLETHICO PHARMA/
SANOFI INDIA
 
P/E (TTM) x -1.1 32.9 - View Chart
P/BV x 0.0 6.3 0.3% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 PLETHICO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
SANOFI INDIA
Dec-16
PLETHICO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3954,560 8.7%   
Low Rs314,400 0.7%   
Sales per share (Unadj.) Rs604.41,028.5 58.8%  
Earnings per share (Unadj.) Rs32.5129.0 25.2%  
Cash flow per share (Unadj.) Rs51.3186.0 27.6%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs473.6753.6 62.8%  
Shares outstanding (eoy) m34.0823.03 148.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.4 8.1%   
Avg P/E ratio x6.634.7 18.9%  
P/CF ratio (eoy) x4.224.1 17.2%  
Price / Book Value ratio x0.55.9 7.6%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m7,262103,174 7.0%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m1,5963,592 44.4%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m20,59823,686 87.0%  
Other income Rs m386708 54.6%   
Total revenues Rs m20,98424,394 86.0%   
Gross profit Rs m2,8185,281 53.4%  
Depreciation Rs m6421,313 48.9%   
Interest Rs m1,59315 10,621.3%   
Profit before tax Rs m9694,661 20.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,691 -8.2%   
Profit after tax Rs m1,1072,970 37.3%  
Gross profit margin %13.722.3 61.4%  
Effective tax rate %-14.336.3 -39.4%   
Net profit margin %5.412.5 42.9%  
BALANCE SHEET DATA
Current assets Rs m18,87715,673 120.4%   
Current liabilities Rs m11,8966,678 178.1%   
Net working cap to sales %33.938.0 89.2%  
Current ratio x1.62.3 67.6%  
Inventory Days Days3676 47.3%  
Debtors Days Days19822 886.6%  
Net fixed assets Rs m9,8618,098 121.8%   
Share capital Rs m341230 147.9%   
"Free" reserves Rs m12,33117,088 72.2%   
Net worth Rs m16,13917,356 93.0%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14625,400 130.5%  
Interest coverage x1.6311.7 0.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.9 66.6%   
Return on assets %8.111.8 69.3%  
Return on equity %6.917.1 40.1%  
Return on capital %12.326.9 45.6%  
Exports to sales %21.424.5 87.3%   
Imports to sales %15.228.0 54.4%   
Exports (fob) Rs m4,4025,801 75.9%   
Imports (cif) Rs m3,1366,627 47.3%   
Fx inflow Rs m4,4027,145 61.6%   
Fx outflow Rs m3,1846,846 46.5%   
Net fx Rs m1,219299 407.5%   
CASH FLOW
From Operations Rs m2,4373,226 75.6%  
From Investments Rs m-6,265-1,555 402.9%  
From Financial Activity Rs m2,490-1,818 -137.0%  
Net Cashflow Rs m-1,337-147 909.6%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 4.3 14.4 29.9%  
FIIs % 5.5 14.6 37.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.5 71.4%  
Shareholders   10,665 15,184 70.2%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS